Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Amphastar Pharma Analyst Ratings and Price Targets | NASDAQ:AMPH | Benzinga
Amphastar Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Amphastar Pharma Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Wells Fargo
Piper Sandler
Wells Fargo
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Amphastar Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/12/2025 | Buy Now | — | JP Morgan | Ekaterina Knyazkova9% | $45 → $30 | Downgrade | Overweight → Neutral | Get Alert |
| 05/08/2025 | Buy Now | — | Wells Fargo | Cerena Chen30% | $40 → $35 | Maintains | Overweight | Get Alert |
| 04/10/2025 | Buy Now | — | Needham | Serge Belanger67% | — | Reiterates | Hold → Hold | Get Alert |
| 03/21/2025 | Buy Now | — | Piper Sandler | David Amsellem72% | $36 → $32 | Maintains | Neutral | Get Alert |
| 02/04/2025 | Buy Now | — | Piper Sandler | David Amsellem72% | $66 → $36 | Downgrade | Overweight → Neutral | Get Alert |
| 11/22/2024 | Buy Now | — | Wells Fargo | Joe Quatrochi47% | → $55 | Initiates | → Overweight | Get Alert |
| 08/08/2024 | Buy Now | — | Piper Sandler | David Amsellem72% | $71 → $66 | Maintains | Overweight | Get Alert |
| 08/08/2024 | Buy Now | — | Needham | Serge Belanger67% | — | Reiterates | → Hold | Get Alert |
| 06/27/2024 | Buy Now | — | Piper Sandler | David Amsellem72% | $71 → $71 | Reiterates | Overweight → Overweight | Get Alert |
| 05/22/2024 | Buy Now | — | Needham | Serge Belanger67% | — | Reiterates | → Hold | Get Alert |
| 05/09/2024 | Buy Now | — | Needham | Serge Belanger67% | — | Reiterates | → Hold | Get Alert |
| 04/10/2024 | Buy Now | — | Needham | Serge Belanger67% | — | Reiterates | → Hold | Get Alert |
| 03/05/2024 | Buy Now | — | JP Morgan | Ekaterina Knyazkova9% | → $60 | Initiates | → Overweight | Get Alert |
| 11/17/2023 | Buy Now | — | B of A Securities | Jason Gerberry59% | → $63 | Initiates | → Neutral | Get Alert |
| 07/25/2023 | Buy Now | — | Jefferies | Glen Santangelo49% | → $70 | Reinstates | Buy → Buy | Get Alert |
| 05/17/2023 | Buy Now | — | Wells Fargo | Jacob Hughes41% | $40 → $44 | Maintains | Equal-Weight | Get Alert |
| 10/25/2022 | Buy Now | — | Piper Sandler | David Amsellem72% | $43 → $40 | Maintains | Overweight | Get Alert |
| 10/21/2022 | Buy Now | — | Jefferies | Glen Santangelo49% | → $36 | Assumes | → Buy | Get Alert |
| 07/29/2022 | Buy Now | — | Capital One | Tim Chiang37% | → $44 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Amphastar Pharma (AMPH) stock?
The latest price target for Amphastar Pharma (NASDAQ:AMPH) was reported by JP Morgan on May 12, 2025. The analyst firm set a price target for $30.00 expecting AMPH to rise to within 12 months (a possible 20.48% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amphastar Pharma (AMPH)?
The latest analyst rating for Amphastar Pharma (NASDAQ:AMPH) was provided by JP Morgan, and Amphastar Pharma downgraded their neutral rating.
When was the last upgrade for Amphastar Pharma (AMPH)?
There is no last upgrade for Amphastar Pharma
When was the last downgrade for Amphastar Pharma (AMPH)?
The last downgrade for Amphastar Pharmaceuticals Inc happened on May 12, 2025 when JP Morgan changed their price target from $45 to $30 for Amphastar Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Amphastar Pharma (AMPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amphastar Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amphastar Pharma was filed on May 12, 2025 so you should expect the next rating to be made available sometime around May 12, 2026.
Is the Analyst Rating Amphastar Pharma (AMPH) correct?
While ratings are subjective and will change, the latest Amphastar Pharma (AMPH) rating was a downgraded with a price target of $45.00 to $30.00. The current price Amphastar Pharma (AMPH) is trading at is $24.90, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
